Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2511 MAD study in healthy adult and elderly subjects
NCT05147337Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E2511 in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd. Primary endpoints: Treatment-emergent Adverse Events up to 56 days, Serious Adverse Events up to 56 days and 2 more. Started Dec 2021; status: completed.
02
Drugs
E2511
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05147337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147337.